Chromadex (NASDAQ:CDXC) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.
Institutional Insider Ownership
17.2% of Chromadex shares are owned by institutional investors. Comparatively, 0.1% of Aurora Cannabis shares are owned by institutional investors. 10.3% of Chromadex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings for Chromadex and Aurora Cannabis, as provided by MarketBeat.com.
Chromadex currently has a consensus target price of $7.00, suggesting a potential upside of 101.15%. Given Chromadex’s higher probable upside, research analysts clearly believe Chromadex is more favorable than Aurora Cannabis.
This table compares Chromadex and Aurora